After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Beam Therapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Beam Therapeutics Inc is $1.74B. A total of 1.94 million shares were traded on the day, compared to an average of 2.09M shares.
In the most recent transaction, FMR LLC sold 48,374 shares of BEAM for 20.50 per share on Jul 30 ’25. After the transaction, the insider now owns 2,073,665 company shares. In a previous transaction on Jul 03 ’25, Simon Amy sold 876 shares at 20.12 per share. BEAM shares that Chief Medical Officer owns now total 64,864.
Among the insiders who sold shares, Simon Amy disposed of 374 shares on Jul 01 ’25 at a per-share price of $16.94. This resulted in the Chief Medical Officer holding 65,740 shares of BEAM after the transaction. In another insider transaction, Bellon Christine sold 5,674 shares at $18.35 per share on Apr 01 ’25. Company shares held by the Chief Legal Officer now total 117,294.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, BEAM has a high of $35.25 and a low of $13.52.
As of this writing, BEAM has an earnings estimate of -$1.03 per share for the current quarter. EPS was calculated based on a consensus of 11.0 estimates, with a high estimate of -$0.79 per share and a lower estimate of -$1.16. The company reported an EPS of -$1.17 in the last quarter
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. BEAM’s latest balance sheet shows that the firm has $965.65M in Cash & Short Term Investments as of fiscal 2021. There were $142.35M in debt and $213.44M in liabilities at the time. Its Book Value Per Share was $10.39, while its Total Shareholder’s Equity was $826.74M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BEAM is Buy with a score of 4.65.
